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1. Introduction 
Synthetic oral steroids were initially developed in the 1940-1950’s. Although their use was 
initially limited by their high cost, as they became more affordable and began to be used for 
treatment of a wide variety of conditions, side effects associated with their use became much 
more prevalent. In fact, glucocorticoid-induced osteoporosis is now the most common 
secondary cause of osteoporosis. Until relatively recently, the mechanism of action of these 
drugs and the mechanisms involved in the development of side effects such as osteoporosis 
and the higher incidence of bone fractures was not known. Although steroids are widely 
viewed as mainly catabolic for bone a distinction needs to be made between physiologic and 
pharmacologic doses of steroids. Recent evidence demonstrates that steroids can clearly be 
anabolic for bone. In this chapter we review recent findings and mechanisms of 
glucocorticoid action on bone and some of the clinical consequences of pharmacologic doses 
of these compounds on bone. 
2. Glucocorticoids and osteoporosis 
Glucocorticoids are among the most potent anti-inflammatory and immunosuppressive 
agents and are key therapeutic agents for the management of chronic inflammatory 
diseases, including rheumatic diseases [1-4], pulmonary disease [5;6], asthma [7-11] and post 
transplantation immunotherapy [12]. However, long-term glucocorticoid therapy (>3 
months) causes bone loss resulting in osteoporosis (glucocorticoid-induced osteoporosis or 
GIOP) [3;4;13-15], a severe-side effect that occurs in 30 – 50% of patients [16-18]. The 
incidence of GIOP is indiscriminate of race, age and gender [19;20]. Children, as young as 4 
years of age, and adolescents who are on glucocorticoid therapy for various pediatric 
disorders, including asthma [20-22], juvenile rheumatoid arthritis [23;24], Crohn's disease 
[25], systemic lupus erythematosus [26;27], and inflammatory bowel disease [28;29] have 
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been reported to endure significant bone density decrease. There is no clearly defined 
threshold for safe use of glucocorticoids. In practice, a dose equal to or greater than 5mg/day 
of prednisone is considered as low, and 10mg/day or more is high. The severity of bone loss 
in GIOP is both time- and dose-dependent. GIOP occurs in two phases: a rapid, early phase 
in which bone mineral density is reduced, within the first 5 to 7 months of therapy, possibly 
as a result of excessive bone resorption, and a slower, progressive phase in which bone 
mineral density declines because of impaired bone formation [30]. Bone loss continues as 
long as treatment is maintained. 
3. Glucocorticoid mechanism of action as anti-inflammatory and 
immunosuppressant drugs 
Glucocorticoids exert their actions via intracellular glucocorticoid receptors (GRs) [31;32]. The 
GR belongs to the ligand-regulated nuclear receptor superfamily [33]. Like other members in 
this superfamily, GR contains three major functional domains: a N-terminal activation domain 
required for transcriptional activation and association with basal transcription factors; a central 
DNA-binding domain (DBD) consisting of two highly conserved zinc finger regions that are 
critical for dimerization, DNA binding, transcriptional activation and repression; and a C-
terminal ligand-binding domain (LBD) that serves as the binding site for glucocorticoids, 
chaperone proteins, and coactivators [34;35]. In the absence of ligand, GR is predominantly 
retained in the cytoplasm as an inactive multi-protein complex consisting of heat shock protein 
(hsp90) and a number of other proteins, including the immunophilins. The binding of 
glucocorticoid triggers a conformational change in the GR and leads to dissociation of the 
multi-protein complex and exposure of a nuclear localization sequence resulting in its nuclear 
translocation. Once in the nucleus, GR, in the form of a homodimer, binds to a palindromic 
glucocorticoid-response element (GRE) in the target gene promoter and activates transcription 
(e.g., of the tyrosine amino transferase gene), or it can bind to a negative GRE (nGRE) to 
repress transcription (e.g., of the osteocalcin gene) [36].  
Glucocorticoids suppress the expression of a panel of inflammatory-relevant genes 
including cytokines [interleukins (IL) and tumor necrosis factors (TNF-,], chemokines 
(Regulated upon Activation Normal T-cell Expressed and Secreted or RANTES, 
Macrophage Inflammatory Protein-1-alpha or MIP-1, Monocyte Chemotactic Protein or 
MCP-1, -3, and -4], inflammatory enzymes (COX-2, iNOS), and adhesion molecules 
(Intercellular Adhesion Molecule 1 or ICAM-1, E-selectin) that play a key role in the 
recruitment of inflammatory cells to the inflammation sites [37-39]. However, most of these 
genes do not have negative GREs in their promoter regions, and therefore, they are not 
directly regulated by the binding of GRs to such regulatory elements. These genes do 
contain NF-B- and/or AP-1-binding sites and are activated through these sites by NF-B 
and/or AP-1 in response to stimuli (cytokines). Thus, one mechanism by which 
glucocorticoids could regulate transcription would be modulation of NF-B or AP-1 DNA-
binding activity. In 1990, three independent groups found cross-talk between GR and AP-1 
[40-42]. In these studies, it was found that activated GR can interact with c-Jun/AP-1 and 
that the formation of a GR-c-Jun complex prevents c-Jun/AP-1 DNA-binding, resulting in 
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the inhibition of gene expression. Later, it was found that the activated GR can associate 
with the p65 subunit of NF-B and inhibit gene activation mediated by NF-B [43;44]. These 
findings led to the establishment of the protein-protein interaction model. 
In 1995, it was found that glucocorticoids induce the expression of a cytoplasmic inhibitor of 
NF-B, the IB- [45;46]. These studies led to the establishment of a second model, the IB- 
upregulation model. This model proposes that glucocorticoids induce the expression of IB-
 and that the newly synthesized IB- sequesters the p65 subunit of the NF-B in the 
cytoplasm and thereby inhibits NF-B nuclear functions. However, this mechanism has been 
challenged by a number of studies. It has now been established that the effect of 
glucocorticoids on IB- expression, and subsequently NF-B nuclear translocation, is cell-
type specific. In some cell types glucocorticoid inhibition of proinflammatory stimuli-
induced p65 nuclear translocation is coupled with the induction of IB- [45-48]. In other 
cell types, however, these two events are uncoupled [49;50]. Moreover, a GR mutant that 
does not enhance IB- expression, is still able to repress NF-B activity [51].  
4. Glucocorticoid effects on bone cells 
Glucocorticoids have both anabolic and catabolic effects on bone. However, the outcome of 
glucocorticoid therapy is a net loss of bone [4;52;53]. Corticosteroid 11β-hydroxysteroid 
dehydrogenase 2 [11β-HSD2] is an enzyme that oxidizes the active form of glucocorticoid 
cortisol to the inactive metabolite cortisone, thus the levels of expression and activity of this 
enzyme is critical for glucocorticoid signaling. In vivo studies show that bone-specific 
transgenic overexpression of 11β-HSD2, under the control of type I collagen promoter, 
impairs osteoblast differentiation and bone acquisition [54-56]. These studies demonstrate 
that the endogenous glucocorticoid signaling is essential for normal skeletal development. 
However, glucocorticoid in excess such as patients with Cushing’s syndrome [22] or the 
patients on glucocorticoid therapy rapidly lose bone mass resulting in osteoporosis. The 
direct effects of glucocorticoids on bone cells are illustrated in Figure 1. 
5. Glucocorticoid effects on bone marrow Mesenchymal Stem Cells 
(MSCs) 
Bone marrow MSCs are multipotent cells that can give rise to several distinct cell lineages, 
including osteoblasts, adipocytes, and chondrocytes [57-60]. Patients on glucocorticoid 
therapy not only lose bone but also accumulate large amounts of marrow fat (fatty marrow), 
indicating that glucocorticoid has altered lineage commitment of MSC to adipocytes at the 
expense of osteoblasts because these two pathways have a reciprocal relationship [61-64]. 
Thus, one possible mechanism by which glucocorticoids alter MSC fate determination is 
through the induction of the master adipogenic regulator peroxisome proliferator-activated 
receptor gamma (PPAR) [65;66], which is transcriptionally activated by the 
CCAAT/enhancer binding protein (C/EBP) family transcription factors in response to 
glucocorticoid [67-70] (Figure 2). Indeed, Weinstein and colleagues showed that 
administration of glucocorticoids to mice reduces the numbers of osteoprogenitor cells [71]. 
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This could be achieved through induction of PPAR since under the same condition bone 
marrow adipogenesis is enhanced [72], and that a reduction in PPAR dosage 
(haploinsufficiency) in mice results in reduced adipogenesis and enhanced osteogenesis 
from bone marrow progenitors [73].  
 
Figure 1. Glucocorticoids bind to the glucocorticoid receptor (GR) and affect mesenchymal stem cell 
(MSC), osteoblast (OB), osteoclast (OC) and osteocyte (Ocyte) function. The net result is decreased bone 
formation and increased bone resorption. ↑ increase;  ↓decrease. 
  
Figure 2. Glucocorticoid reduces the number of osteoprogenitors from MSC by promoting adipogenic 
differentiation pathway. Glucocorticoid induces the expression of C/EBP family transcription factors 
that directly activate the transcription of PPAR, the master regulator of adipogenesis, and shifts the 
lineage commitment of MSCs to adipocyte pathway, thus reducing the number of osteoprogenitor cells.  
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6. Glucocorticoid effects on osteoblasts and osteocytes 
It has been known for decades that glucocorticoid inhibits bone formation [52;74], but only 
recently have we realized that glucocorticoids directly target bone cells. By administering a 
high dose of prednisolone to mice, Weinstein and colleagues found that glucocorticoid 
induces the death of mature osteoblasts and osteocytes [71;75]. In the same study, the 
authors also showed that the same is true in bone biopsy samples obtained from patients 
with glucocorticoid-induced osteoporosis. These results were further strengthened in a 
transgenic mouse model, in which the glucocorticoid signaling is disrupted by 
overexpression of 11β-HSD2 specifically in osteoblasts. The study showed that the 11β-
HSD2 transgenic mice are protected from glucocorticoid-induced osteoblasts and osteocytes 
apoptosis and suppression of bone formation [76]. These studies demonstrate that 
glucocorticoids cause bone loss by restricting the supply of bone building cells, the 
osteoblasts, and by interfering with the communication network within bone environment 
via osteocyte death. The osteocytes are the mechanosensory cells that detect and send 
signals for bone formation in response to damages caused by mechanical loading and 
unloading [77;78].  
7. Glucocorticoid effects on osteoclasts 
Osteoclasts are bone resorbing cells and play a key role in the maintenance of bone 
homeostasis through bone remodeling. In patients, glucocorticoid-induced osteoporosis 
features a rapid early phase increase in bone resorption, followed by a slow progressive 
decrease in bone formation [52]. Earlier studies showed that glucocorticoids stimulate 
osteoclast differentiation and increase their activity [72;79;80]. It is now recognized that 
glucocorticoids increase the longevity of osteoclasts but may inhibit their bone resorptive 
activity [81;82]. Moreover, a recent study suggests that glucocorticoids do not inhibit, but 
modify osteoclast resorptive behavior, making osteoclasts erode bone surfaces over long 
distances without interruption [83]. 
8. Glucocorticoid-induced Leucine Zipper (GILZ): A new glucocorticoid 
anti-inflammatory effect mediator  
The protein-protein interaction and the IB- upregulation models described earlier in this 
chapter were established prior to the discovery of a glucocorticoid-inducible protein named 
glucocorticoid-induced leucine zipper (GILZ), which was identified in 1997 [84]. GILZ is a 
member of the leucine zipper protein family [84;85] and belongs to the transforming growth 
factor-beta (TGF-)-stimulated clone-22 (TSC-22d3) family of transcription factors [86;87]. 
Members of this family of proteins contain three distinct domains; an N-terminal domain 
containing a TSC box (N-Ter), a middle leucine zipper domain (LZ), and a C-terminal poly-
proline rich domain (PRR).  
Unlike IB-, which is induced by glucocorticoids in certain cell types [49;50;88], GILZ is 
induced by glucocorticoids virtually in all cell types examined so far, including bone 
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marrow mesenchymal stem cells, osteoblasts, adipocytes, macrophages and epithelial cells 
[89]. In vitro studies show that overexpression of GILZ protects T-cells from apoptosis 
induced by anti-CD3 monoclonal antibody, but not other apoptosis-inducing agents such as 
dexamethasone, ultraviolet irradiation, starvation, or triggered by cross-linked anti-Fas mAb 
[84]. T-cell-specific transgenic overexpression of GILZ results in thymocyte apoptosis ex vivo, 
possibly through down-regulation of Bcl-xL [90]. The in vitro actions of GILZ have been 
shown to be mediated through direct protein-protein interactions between GILZ and NF-B, 
and between GILZ and AP-1 [86;91;92]. The interaction between GILZ and NF-B blocks 
NF-B nuclear translocation and DNA-binding, and the interaction with AP-1 inhibits the 
binding of AP-1 to its DNA elements [91;92]. GILZ also interacts directly with the mitogen-
activated protein kinase (MAPK) family members, Ras and Raf-1, resulting in inhibition of 
Raf-1 phosphorylation and subsequently, inhibition of MEK/ERK-1/2 phosphorylation and 
AP-1-dependent transcription [86;93]. Moreover, GILZ can deactivate macrophages [94], 
inhibit proinflammatory cytokine-induced inflammatory enzymes such as cyclooxygenase-2 
[95], inhibit IL-2/IL-2 receptor and IL-5 expression [91;96], and stimulate the production of 
anti-inflammatory IL-10 by immature dendritic cells, thereby, preventing the production of 
inflammatory chemokines by CD40L-activated dendritic cells [97]. These studies 
demonstrate that GILZ is a glucocorticoid anti-inflammatory effect mediator and utilizes  
very similar mechanisms, to those  GR uses [98]. 
9. GILZ mediates the anabolic effect of glucocorticoids 
GILZ is a direct GR target gene with several GREs present in its promoter region [99]. In the 
absence of glucocorticoid stimulation GILZ is expressed at a very low basal level. However, 
in the presence of glucocorticoid, GILZ expression is rapidly induced (Figure 3] but GR is 
also activated, and the activated GR negatively impacts bone, both directly (i.e., inhibits 
osteocalcin gene transcription) and indirectly through other pathways as illustrated (Figure 
4]. Because of that, it is impossible to determine the role of GILZ in osteoblast differentiation 
and bone formation without the influence of GR, which plays a negative role and may 
override GILZ actions. To further study this problem, a retrovirus-mediated GILZ 
overexpression system was established in bone marrow MSCs/osteoprogenitor cells. Studies 
carried out in this system showed that GILZ has potent pro-osteogenic activity as 
demonstrated by significantly increased alkaline phosphatase activity, enhanced 
mineralized bone nodule formation, and the expression of osteoblast-associated genes such 
as Runx2, type I collagen, alkaline phosphatase, and osteocalcin [100]. Furthermore, our 
recent studies have shown that overexpression of GILZ can antagonize the inhibitory effect 
of TNF- on MSC osteogenic differentiation [101]. Possible mechanisms underlying this 
antagonism may include GILZ inhibition of TNF--induced ERK/MAP kinase activation, 
which has been shown to be responsible for TNF- down-regulation of a key osteogenic 
factor Osx [102;103], and inhibition of TNF--induced expression of E3 ubiquitin ligase 
Smurf proteins, which have been shown to accelerate the degradation of Runx2 protein [104-
106]. 
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Figure 3. GILZ enhances MSC osteogenic differentiation by shifting MSC lineage preference to 
osteogenic pathway. 
10. GR mediates the catabolic effects of glucocorticoids 
There are many glucocorticoid effectors involved in the regulation of bone development or 
metabolism through different pathways. However, it was only recently demonstrated that 
the GR was directly responsible for glucocorticoid-induced bone loss in vivo. Using a bone-
specific GR knockout mouse model, Rauch et al showed that glucocorticoids are unable to 
induce bone loss or to inhibit bone formation in these mice because the GR-deficient 
osteoblasts become refractory to glucocorticoid-induced apoptosis, inhibition of 
proliferation, and differentiation [107]. Interestingly, data from this study also demonstrated 
that GR-deficiency results in a low bone mass phenotype, confirming the previous studies 
that the endogenous glucocorticoid signaling is critical for normal bone acquisition [54-56]. 
Other evidence supporting the role of GR in glucocorticoid-induced bone loss includes: 1] 
the glucocorticoid-activated GR binds directly to the negative glucocorticoid response 
elements (nGREs) in the promoter region of the osteocalcin (Ocn) gene, an osteoblast-
specific gene that plays an important role in bone mineralization, and inhibit its 
transcription [36;108]; 2] GR transcriptionally activates the expression of MAP kinase 
phosphatase-1 (MKP-1] [109], which inactivates MAP kinase and thus inhibits osteogenic 
differentiation [64;110;111]; and 3] GR can physically interact with and inhibit the 
transcriptional functions of Smad3, an intracellular signaling mediator of transforming 
growth factor-beta (TGF-) [112] (Figure 4]. Glucocorticoids have been known to antagonize 
TGF- action in bone [113-115] and TGF- stimulates osteoprogenitor cell proliferation [116-
119] and attract osteoprogenitor cells to the remodeling sites during bone remodeling [120]. 
It is important to note that while the catabolic effects of glucocorticoids are often associated 
with long-term glucocorticoid excess [1-4;7], a short term exposure to glucocorticoid seems 
beneficial; for example, treatment of bone marrow stromal cells or osteoblasts with 
dexamethasone enhances, rather than inhibits, alkaline phosphatase (ALP) activity. The ALP 
is expressed at the early stage of osteoblast differentiation program and the increase of ALP 
expression or activity marks the entry of cells into the osteoblast lineage. 
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Figure 4. GR inhibits MSC proliferation, ERK activation and Ocn expression. Ligand-bound GR 
physically interacts with: 1] TGF- signaling mediator Smad3 and disrupts its transcriptional activity; 2] 
Activates mkp-1 transcription, by binding to GRE in the mkp-1 promoter region, resulting inhibition of 
ERK activation; and 3] Suppresses Ocn expression by binding to nGRE in the Ocn promoter region. 
11. Glucocorticoid-Induced Osteoporosis (GIOP) 
Although glucocorticoids are an essential hormone for survival and normal function, when 
present in excess (pharmacologic doses) lead to a number of serious side effects including 
bone loss and fractures. In fact, it is estimated that 30-50% of patients chronically exposed to 
high levels of glucocorticoids will develop a bone fracture [121]. Glucocorticoid excess can 
result from either endogenous (Cushing’s) or exogenous (iatrogenic) sources. 
Glucocorticoids are widely used for the treatment of a variety of inflammatory and 
autoimmune conditions. It is estimated that 0.5% of the population receives steroid therapy 
and exogenous steroids are thus the most common cause of secondary osteoporosis [122]. 
There has been a lot of discussion on the dose, duration and mode of administration of 
steroids and the impact on the development of osteoporosis. There has been a lot of debate 
on a “safe” dose for glucocorticoid replacement. Doses as low as 2.5 mg of prednisolone 
have been reported to result in osteoporosis [122]. Even patients on “physiologic” 
glucocorticoid replacement for Addison’s disease have been reported to have lower bone 
density than controls, although clearly many of these patients were overreplaced with 
steroid therapy [123]. Further, steroids even when given in an intermittent, rather than 
continuous fashion, or in an inhaled rather than oral fashion, are still associated with an 
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increased risk of fracture. In treatment guidelines by the American College of Rheumatology 
in 2010, it was recommended that for patients with low fracture risk receiving more than 7.5 
mg of prednisolone equivalents for more than 3 months receive some form of therapy for 
fracture prevention. In contrast for patients at high fracture risk it was recommended that 
they receive some form of therapy even at glucocorticoid doses lower than 5 mg and even 
for periods for less than one month [124]. 
12. Mechanism 
Glucocorticoids have multiple effects on bone and bone cells. In addition, in cases where the 
glucocorticoids are given to treat systemic inflammatory conditions (e.g. rheumatoid 
arthritis), the underlying condition also contributes to bone loss. Glucocorticoids also inhibit 
endogenous production of sex steroids (testosterone and estrogen) in addition to production 
of adrenal androgens, all of which may have protective effects against bone loss [125]. 
Further, prolonged high dose glucocorticoid use results in both muscle weakness thus 
predisposing to an increased number of falls and muscle wasting. Bone-muscle interactions 
may also contribute to maintaining bone health. Glucocorticoids also decrease intestinal 
calcium absorption thus further predisposing to osteoporosis. Recently, effects of 
glucocorticoids on decreasing bone vasculature, has also been implicated as a potential 
mechanism for glucocorticoid effects on bone [126]. There also seems to be an age-
dependence of glucocorticoid effects on bone. The likelihood of fractures with 
glucocorticoids appears to increase with increasing patient age. Glucocorticoid-induced 
bone loss appears to be biphasic with an initial rapid phase of bone loss of 5-15% /year 
followed by a more sustained bone loss rate of 2% [121].  
Glucocorticoids affect all bone cells, they result in osteocytic and osteoblastic apoptosis and 
decreased function of both osteoclasts and osteoblasts. However, they decrease osteoclastic 
apoptosis. Thus, the net effect is reduced bone formation and increased bone breakdown. 
Trabecular bone seems to be particularly sensitive to the detrimental effects of steroids 
resulting in a higher incidence of vertebral and femoral neck fractures [121]. Vertebral 
compression fractures are commonly missed since only about 30% of them are symptomatic. 
A study by Angeli et al [127] which examined the prevalence of vertebral fractures in 
patients receiving glucocorticoids for a variety of autoimmune conditions determined that 
over 37% of patients had at least one asymptomatic vertebral compression fracture and 
more than 14% had two or more asymptomatic fractures.  
Glucocorticoid effects on bone appear to be generally reversible and once therapy is stopped 
bone repair occurs over the year following drug cessation. Thus, if feasible, steroid cessation 
may be the therapy of choice for GIOP. 
13. Diagnosis 
Determining fracture risk for patients on steroids is difficult since even patients with normal 
bone densitometry on steroids have a higher fracture risk. Current use of steroids is one of 
the risk factors used in the calculation of the FRAX (Fracture Risk Assessment) score. 
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However a recent joint position statement by the International Society for Clinical 
Densitometry and the International Osteoporosis Foundation concluded that when using 
the FRAX tool there probably was an underestimation of fracture risk with daily prednisone 
doses greater than 7.5 mg and an overestimation of fracture risk with daily prednisone 
doses of less than 2.5 mg. In addition, FRAX probably underestimated fracture risk when 
high dose inhaled steroids were used. Finally, it was concluded that for patients with 
adrenal insufficiency receiving appropriate replacement steroid doses this not be included 
in the FRAX calculation [128].  
The American College of Rheumatology recommends that some form of therapy be 
considered for all patients receiving prolonged steroid therapy and that for those who have 
a bone densitometry test (Dual energy x-ray absorptiometry or DXA), a T-score of less than -
1.0 be considered abnormal [125].  
14. Therapy 
Since glucocorticoids interfere with intestinal calcium absorption, all patients about to start 
glucocorticoid therapy should be placed on calcium and vitamin D replacement. 
Antiresorptive agents such as bisphosphonates (both oral and IV) have been used for the 
therapy of GIOP, are effective in decreasing the increased fracture risk associated with 
steroids and are approved for this indication. However, as discussed by Teitelbaum et al. 
[129], although initial use of steroids is associated with increased bone resorption (osteoclast 
mediated and related to decreased osteoclastic apoptosis and a situation in which 
antiresorptive use makes sense), more prolonged steroid use is associated with decreased 
bone formation and antiresorptive agents have the theoretical possibility of making things 
worse by further suppressing a low bone turnover state. Thus, use of an anabolic agent such 
as teriparatide (synthetic parathyroid hormone) for treatment of GIOP would appear more 
appropriate. In fact in a clinical trial, comparing alendronate vs. teriparatide for 18 months 
in 428 men/women with established osteoporosis and who had received at least 5mg of 
prednisone for at least 3 months, teriparatide was significantly more effective in both 
increasing bone mineral density at the spine [7.2 vs 3.4%) and in decreasing new vertebral 
fractures [0.6% vs 6.1%) [130]. Of note, this was a secondary instead of a primary 
osteoporosis prevention trial and there was a greater incidence of side effects associated 
with teriparatide use as compared to controls [131]. In addition, use of teriparatide by 
patients is currently limited to two years, thus alternative and better forms of therapy for 
GIOP need to be developed. 
15. Conclusion 
Although adverse side effects of glucocorticoids on bone have been long recognized, both 
from endogenous sources as described by Harvey Cushing in the 1930’s or from exogenous 
sources after development of glucocorticoids in the 1950’s the mechanisms involved in this 
process have only recently began to be understood. It is clear that although physiologic 
levels of glucocorticoids are important in normal bone development, pharmacologic doses 
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result in a high level of fractures, particularly of vertebral bone. Thus, it would seem that 
glucocorticoids have both anabolic and catabolic actions on bone. Data from our labs and 
from others suggest that GILZ may be an important mediator of GR’s anabolic actions and 
thus may be an attractive therapeutic target for drug development. 
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